Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Anna Kornietskaya"'
Autor:
Anna Kornietskaya, Sevindzh Evdokimova, Andrei Kachmazov, Alexander. Fedenko, Larisa Bolotina, Dmitriy Sidorov, Nadezhda Volchenko, Natalia Goeva, Anastasia Govaleshko, Andrey Kaprin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Solid pseudopapillary neoplasm (SPN) of the pancreas is an extremely rare tumor, associated with favorable prognosis and long-term survival in patients with advanced disease. However, limited data exist on systemic therapy for such patients. Herein,
Externí odkaz:
https://doaj.org/article/02b777128c3f4e2ab4418068bf7b92c3
Autor:
Andrei Kachmazov, Larisa Bolotina, Anna Kornietskaya, Olesya Kuznetsova, Maxim Ivanov, Alexander Fedenko
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various
Externí odkaz:
https://doaj.org/article/15215176b97f49e896e659eee237e11e
Publikováno v:
World Journal of Oncology. 14:26-31
Autor:
Ilya Kolobaev, Vladimir Khomyakov, Anna Chayka, Anna Utkina, Dmitriy Sobolev, Andrey Ryabov, Anna Kornietskaya, Farkhad Vindiza
Publikováno v:
Problems in oncology. 66:50-57
Metastatic gastric cancer is associated with poor prognosis despite of advances in chemotherapy and surgery. According to current clinical guidelines surgical treatment for stage IV gastric cancer patients is indicated only for urgent complications.
Autor:
Natalya Buevich, Daniil Stroyakovskiy, Tatyana Ionova, Rashida Orlova, Konstantin Laktionov, Fedor Moiseenko, N. Porfir’eva, Sergey Orlov, Mikhail M Kramchaninov, Valeriy Breder, Dilorom Latipova, Mariya Okruzhnova, Yelena Filippova, Ye. Kushniruk, Svetlana Protsenko, Anna Kornietskaya, Alla L. Arzumanyan, Larisa Bolotina, Anna Danilova, K. A. Sarantseva, Tatyana Nikitina, Anna Zinkovskaya
Publikováno v:
Problems in oncology. 65:99-105
The preliminary results of observational study focused on clinical efficacy and safety of nivolumab (Nivo) treatment as >2nd line in patients with advanced refractory NSCLC as well as on quality of life (QoL) before and during treatment are presented
Autor:
Anna Kornietskaya, Larisa Bolotina
Publikováno v:
Onkologiya. Zhurnal imeni P.A.Gertsena. 11:11
Autor:
Rashida Orlova, Svetlana Protsenko, Anna Kornietskaya, Larisa Bolotina, Dilorom Latipova, Sergey Orlov, Daniil Stroyakovskiy, Tatiana Nikitina, Evgeny Ledin, Anna Zinkovskaya, Tatyana Ionova, Anastasia Mochalova, E. Filippova, Eugenia K Kushniruk, Anastasia Danilova, Ksenia A. Sarantseva, Mikhail M Kramchaninov, Fedor Moiseenko, Konstantin Laktionov, Valeriy Breder
Publikováno v:
Journal of Clinical Oncology. 37:e20567-e20567
e20567 Background: We aimed to evaluate clinical and quality of life (QoL) outcomes of Nivo as 2+ line treatment in NSCLC pts within expanded access program and real world practice. Methods: Adult pts with advanced refractory NSCLC were enrolled in 1
Autor:
Tatyana Ionova, Konstantin Laktionov, Dilorom Latipova, Valeriy Breder, Svetlana Protsenko, Anna Kornietskaya, Rashida Orlova, Mikhail M Kramchaninov, Natalia N. Buevich, Eugenia K Kushniruk, Anna Zinkovskaya, Alla L. Arzumanyan, Ksenia A. Sarantseva, Sergey Orlov, Daniil Stroyakovskiy, Larisa Bolotina, Fedor Moiseenko, Elena A. Filippova, Anastasia Danilova, Tatiana Nikitina
Publikováno v:
Journal of Clinical Oncology. 36:e21126-e21126
e21126Background: We aimed to evaluate quality of life (QoL) in advanced refractory NSCLC pts and clinical outcomes of nivolumab (Nivo) as ≥ 2nd line treatment within the expanded access program in...
Autor:
Konstantin Laktionov, Svetlana Protsenko, Anna Kornietskaya, Natalya Buevich, Fedor Moiseenko, E. Kushniruk, Sergey Orlov, Valeriy Breder, Daniil Stroyakovskiy, Danilova Ab, Tatyana Ionova, Alla L. Arzumanyan, Dilorom Latipova, Rashida Orlova, Tatyana Nikitina, E. Filippova, M. Kramchaninov, Larisa Bolotina, K. A. Sarantseva
Publikováno v:
Web of Science
Autor:
Larisa Bolotina, Daniil Stroyakovskiy, Valeriy Breder, Dilorom Latipova, Rashida Orlova, Daria A Lipatova, Fedor Moiseenko, Anastasia Danilova, Elena A. Filippova, Tatiana Nikitina, Ksenia A. Sarantseva, Konstantin Laktionov, Sergey Orlov, Tatyana Ionova, Natalia N. Buevich, Eugenia K Kushniruk, Svetlana Protsenko, Anna Kornietskaya, Mikhail M Kramchaninov, Alla L. Arzumanyan
Publikováno v:
Journal of Clinical Oncology. 35:e14593-e14593
e14593 Background: Therapy with immune checkpoint inhibitors (ICI) changed the paradigm of treatment in many solid tumors including NSCLC. Recently several ICI were approved for NSCLC second and first line. By now data on Nivo benefits/risks in NSCLC